Circulating insulin-like growth factor binding protein-3 predicts one-year outcome after ischemic stroke

Tools

Item Type:	Article
Title:	Circulating insulin-like growth factor binding protein-3 predicts one-year outcome after ischemic stroke
Creators Name:	Ebinger, M., Ipsen, N., Leonards, C.O., Empl, L., Hanne, L., Liman, T., Mai, K., Strasburger, C.J., Spranger, J. and Endres, M.
Abstract:	Background: Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) have been ascribed neuroprotective effects. We sought to determine whether levels of IGF-1 and IGFBP-3 predict functional outcome after ischemic stroke. Methods: IGF-1 and IGFBP-3 levels were measured in the first week after stroke in patients with first ischemic stroke who were enrolled in the Berlin Cream&Sugar Study. National Institutes of Health Stroke Scale (NIHSS) was collected at admission. Lesion volume was determined from acute MRI if available. Functional outcome according to the modified Rankin Scale (mRS) was assessed after one year. In multivariate analyses we identified parameters associated with unfavourable functional outcome (mRS>2). Results: We included 100 patients. 21 patients had an unfavourable functional outcome. IGF-1 levels were<- 2 standard deviation score (SDS) in 7 patients, and>2 SDS in 12 patients. IGFBP-3 levels were<the 5(th) percentile in 13 patients, and no patient had IGFBP-3 levels>the 95(th) percentile. Low levels of IGFBP-3 (p=0.002), NIHSS at admission (p=0.043) and age (p=0.001) were associated with unfavourable functional outcome in the univariate analyses. In multivariate analysis including IGFBP-3, IGF-1, age, thrombolysis and NIHSS only low IGFBP-3 levels (OR 7.2, 95%CI 1.8-29.0, p=0.006) were associated with unfavourable functional outcome. If lesion volume was incuded (n=71), only IGFBP-3 levels (OR 7.2, 95%CI 1.5-35.5, p=0.015) were associated with unfavourable functional outcome. Conclusion: IGFBP-3 levels after ischemic stroke may independently predict functional outcome after one year.
Keywords:	Acute Cerebral Infarction, Neuroprotectors, mRS
Source:	Experimental and Clinical Endocrinology & Diabetes
ISSN:	0947-7349
Publisher:	Thieme / Barth
Volume:	123
Number:	8
Page Range:	461-465
Date:	September 2015
Official Publication:	https://doi.org/10.1055/s-0035-1554632
PubMed:	View item in PubMed

Repository Staff Only: item control page